Abstract
Multiple studies had demonstrated that surgical resection provided better overall survival (OS) than other treatments even for BCLC stage B or C hepatocellular carcinoma (HCC) patients in China. However, there was no standard adjuvant therapy to decrease the risk of post-operative tumor relapse. Several studies showed transcatheter arterial chemoembolization (TACE) as adjuvant therapy could reduce tumor recurrence and prolong the disease-free survival (DFS) and OS. However, its effect is not satisfactory.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
